Literature DB >> 19422935

Genetic risk profiling and prediction of disease course in Crohn's disease patients.

Liesbet Henckaerts1, Kristel Van Steen, Isabel Verstreken, Isabelle Cleynen, Andre Franke, Stefan Schreiber, Paul Rutgeerts, Séverine Vermeire.   

Abstract

BACKGROUND & AIMS: Clinical presentation at diagnosis and disease course of Crohn's disease (CD) are heterogeneous and variable over time. Early introduction of immunomodulators and/or biologicals might be justified in patients at risk for disease progression, so it is important to identify these patients as soon as possible. We examined the influence of recently discovered CD-associated susceptibility loci on changes in disease behavior and evaluated whether a genetic risk model for disease progression could be generated.
METHODS: Complete medical data were available for 875 CD patients (median follow-up time, 14 years; interquartile range, 7-22). Fifty CD-associated polymorphisms were genotyped. Kaplan-Meier survival analyses, multiple logistic regression, and generalized multifactor dimensionality reduction analyses (GMDR) were performed, correcting for follow-up time.
RESULTS: Homozygosity for the rs1363670 G-allele in a gene encoding a hypothetical protein near the IL12B gene was independently associated with stricturing disease behavior (odds ratio [OR], 5.48; 95% confidence interval [CI], 1.60-18.83; P = .007) and with shorter time to strictures (P = .01), especially in patients with ileal involvement (P = .0002). Male patients carrying at least one rs12704036 T-allele in a gene desert had the shortest time to non-perianal fistula (P < .0001). The presence of a C-allele at the CDKAL1 single nucleotide polymorphism rs6908425 and the absence of NOD2 variants were independently associated with development of perianal fistula (OR, 8.86; 95% CI, 1.13-69.78; P = .04 and OR, 0.56; 95% CI, 0.38-0.83; P = .004, respectively), particularly when colonic involvement and active smoking were present.
CONCLUSIONS: CD-associated polymorphisms play a role in disease progression and might be useful in identifying patients who could benefit from an early top-down treatment approach.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19422935     DOI: 10.1016/j.cgh.2009.05.001

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  46 in total

1.  Predictors of aggressive inflammatory bowel disease.

Authors:  Andres J Yarur; Sebastian G Strobel; Amar R Deshpande; Maria T Abreu
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-10

Review 2.  Assessing gene-gene interactions in pharmacogenomics.

Authors:  Hsien-Yuan Lane; Guochuan E Tsai; Eugene Lin
Journal:  Mol Diagn Ther       Date:  2012-02-01       Impact factor: 4.074

Review 3.  Have genomic discoveries in inflammatory bowel disease translated into clinical progress?

Authors:  Adam V Weizman; Mark S Silverberg
Journal:  Curr Gastroenterol Rep       Date:  2012-04

Review 4.  Emerging significance of NLRs in inflammatory bowel disease.

Authors:  Beckley K Davis; Casandra Philipson; Raquel Hontecillas; Kristin Eden; Josep Bassaganya-Riera; Irving C Allen
Journal:  Inflamm Bowel Dis       Date:  2014-12       Impact factor: 5.325

5.  NOD2 gene mutations in ulcerative colitis: useless or misunderstood?

Authors:  Paulo Freire; Ricardo Cardoso; Pedro Figueiredo; Maria M Donato; Manuela Ferreira; Sofia Mendes; Ana Margarida Ferreira; Helena Vasconcelos; Francisco Portela; Carlos Sofia
Journal:  Int J Colorectal Dis       Date:  2014-03-22       Impact factor: 2.571

6.  NKX2-3 and IRGM variants are associated with disease susceptibility to IBD in Eastern European patients.

Authors:  Nora Meggyesi; Lajos S Kiss; Magdalena Koszarska; Martin Bortlik; Dana Duricova; Laszlo Lakatos; Tamas Molnar; Martin Leniček; Libor Vítek; Istvan Altorjay; Maria Papp; Zsolt Tulassay; Pal Miheller; Janos Papp; Attila Tordai; Hajnalka Andrikovics; Milan Lukas; Peter Laszlo Lakatos
Journal:  World J Gastroenterol       Date:  2010-11-07       Impact factor: 5.742

Review 7.  Top-down therapy for IBD: rationale and requisite evidence.

Authors:  Geert R D'Haens
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-02       Impact factor: 46.802

8.  Evaluation of "top-down" treatment of early Crohn's disease by double balloon enteroscopy.

Authors:  Rong Fan; Jie Zhong; Zheng-Ting Wang; Shu-Yi Li; Jie Zhou; Yong-Hua Tang
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

9.  CARD15 mutations and colorectal cancer in a South European country.

Authors:  Paulo Freire; Francisco Portela; Maria M Donato; Pedro Figueiredo; Manuela Ferreira; Pedro Amaro; Anabela Sá; Paulo Andrade; Hermano Gouveia; Carlos Sofia
Journal:  Int J Colorectal Dis       Date:  2010-07-30       Impact factor: 2.571

10.  Molecular reclassification of Crohn's disease by cluster analysis of genetic variants.

Authors:  Isabelle Cleynen; Jestinah M Mahachie John; Liesbet Henckaerts; Wouter Van Moerkercke; Paul Rutgeerts; Kristel Van Steen; Severine Vermeire
Journal:  PLoS One       Date:  2010-09-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.